RecruitingPHASE1, PHASE2NCT06045910
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Studying Nodal T-follicular helper cell lymphoma, follicular type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cancer Research UK
- Principal Investigator
- Sridhar Chaganti, DrUniversity Hospital Birmingham NHS Foundation Trust
- Intervention
- ALETA-001(drug)
- Enrollment
- 84 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2024 – 2029
Study locations (7)
- University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- Cambridge University Hospitals, Cambridge, United Kingdom
- St James's University Hospital, Leeds, United Kingdom
- University Hospital London Hospital, London, United Kingdom
- Manchester Royal Infirmary, Manchester, United Kingdom
- The Christie Hospital, Manchester, United Kingdom
- Royal Marsden Hospital, Sutton, United Kingdom
Collaborators
Aleta BioTherapeutics
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06045910 on ClinicalTrials.govOther trials for Nodal T-follicular helper cell lymphoma, follicular type
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06347653Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)Peking University
- RECRUITINGPHASE1, PHASE2NCT05230680Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)Won Seog Kim
See all trials for Nodal T-follicular helper cell lymphoma, follicular type →